PINELLAS COUNTY, Fla. — Hundreds of seniors say they’re in a bind and could end up with nowhere to go, because of the way their storm-damaged mobile homes have been assessed. In March, 235 homeowners ...

Feb. 12 (UPI) --Sales of existing homes greatly declined in January despite mortgage rates coming down, a report from the National Association of Realtors released Thursday says. Existing home sales, ...

WASHINGTON, Feb 12 (Reuters) - U.S. existing home sales tumbled to the lowest level in more than two years in January as falling inventory raised house prices. Home sales dropped 8.4% last month to a ...

Existing home sales dropped 8.4% in January to 3.91 million units, with weather and rate uncertainty cited as key factors. Affordability improved for the seventh month. AI Summary The pace of existing ...

Eleven staffers on the newscast have taken buyouts offered in late January. By Rick Porter Television Business Editor A number of production staffers at the CBS Evening News has taken buyouts — and ...

FRESNO, Calif. (KFSN) -- Student borrowers can expect new repayment options available to them for the upcoming school year. "The 'One Big Beautiful Bill' was signed into law on July 4, 2025, but a lot ...

ATLANTA — State School Superintendent Richard Woods announced Georgia would continue its expansion of fine arts instruction across the state, including new high school pathways and a push for ...

Feb 2 (Reuters) - Cboe Global Markets (CBOE.Z), opens new tab is in the early stages of exploring a new regulated product that would use an options structure to offer all-or-none payouts, a source ...

CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...

When war erupted in Europe in 1939, Britain urgently needed modern fighters and turned to the United States for help. Unsatisfied with existing options, British officials placed their hopes in a bold ...

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer ASCO Guidelines provide ...